Understanding the mechanisms by which estrogens affect cardiovascular disease risk, including the role of variation in the gene for estrogen receptor ␣ (ESR1), may be key to new treatment strategies. We investigated whether the CC genotype at ESR1 c.454-397T>C is associated with increased risk among men. Study of more than 7000 whites in 5 cohorts from 4 countries provided evidence that genotype CC, present in roughly 20% of individuals, is a risk factor for nonfatal acute myocardial infarction (odds ratio‫;44.1؍‬ P<0.0001), after adjustment for established cardiovascular risk factors. After exclusion of younger subjects from 2 cohorts, because of age interaction, the odds ratio increased (to 1.63).
I n the Rotterdam Study, an estrogen receptor ␣ (ESR1) haplotype, including the ESR1 c.454-397 T allele, also referred to in previous studies as the p allele of the PvuII site in intron 1 (rs2234693), was associated with significantly increased risk of myocardial infarction (MI) among postmenopausal women (for homozygous carriers, the relative risk was 2.48; the 95% confidence interval [CI], 1.22 to 5.03 after adjusting for known cardiovascular risk factors). 1 In men, however, no statistically significant association was found (relative risk, 0.82; 95% CI, 0.49 to 1.38). These results may be viewed as at odds with previous reports by us and others of a significantly higher risk of MI among men with the c.454-397CC genotype (PP of PvuII). 2, 3 We aimed to clarify whether the CC genotype at ESR1 c.454-397TϾC is associated with increased odds of nonfatal MI among men.
Materials and Methods
We included only cohorts of white men not recruited on the basis of coronary heart disease risk factors (Table I in the online data supplement, available at http://circres.ahajournals.org). We studied men from the prospective population-based Second Northwick Park Heart Study (NPHSII) in the United Kingdom 4 and 2 case-control studies of MI from Poland and the United States, selected from the Global Repository at Genomics Collaborative. 5 Here we present a metaanalysis of the results of these studies and published results from the Framingham 3 and Rotterdam Studies 1 : a total of more than 7000 men with detailed covariate information, including 731 men with acute, nonfatal MI. We also carried out analyses of total MI, including 47 fatal MIs in NPHSII and the Rotterdam Study, and ischemic heart disease (IHD) in the 3 prospective studies. Unless specified, odds ratios (ORs) are from a fixed effects model, adjusted for age, body mass index, serum total cholesterol level, hypertension, diabetes, and smoking status.
Results
The mean (SD) values for age (supplemental Table I 
Discussion
Sixty-eight percent of the weight of our model for nonfatal MI is derived from previously unstudied cohorts, making it unlikely that our results have been affected by publication bias. Our findings also show consistency across 5 white cohorts from 4 countries, providing additional evidence that the association is real and not attributable to population stratification or a context dependent factor. 6 There was wide variability in participant age across the 5 studies, and we obtained evidence that the association we report may be affected by subject age. That a time window of maximum effect exists for this ESR1 genotype (which may itself vary with characteristics such as ethnicity, diet, estrogen levels, and established risk factors for MI) would be compatible with previous results and recent negative findings from an MI case-control study of men with mean age in the early sixties (SD 12 years), 7 and should be tested in other populations including studies of hormone replacement therapy. 8 Fatality for MI may potentially be affected by ESR1 variation and the 2 case-control studies recruited only survivors of MI. Therefore, only nonfatal cardiovascular events were initially included in this metaanalysis. Secondary analyses including 47 fatal MIs provided results that were significant; however, only 8.5% of subjects with a fatal MI had an ESR1 c.454-397CC genotype. Although not statistically significant, there was a trend toward decreased risk of fatal MI in subjects with c.454-397CC genotype, in both studies that included such events. Although this initially appears to be at odds with the findings for nonfatal MIs, results from women in the Rotterdam Study 1 included higher mortality in the year after IHD among women without c.454-397CC genotype. This is consistent with the highest OR being from the Framingham Study, where survival for blood sampling at the sixth examination cycle, almost 3 decades after the start of the study, was required for inclusion and might, in part, underlie the results we observe for nonfatal MIs. A genetic basis for increased risk of fatality among older subjects might be a reason for the observed interaction with age. Further studies 1, 10 A study of postmenopausal women reported that c.454-397CC genotype was associated with more severe atherosclerosis at baseline than in other genotypes but progressed more slowly in response to hormone-replacement therapy. 11 The alleles of a polymorphic TA repeat, in the ESR1 promoter, in strong linkage disequilibrium with c.454-397C, have been associated with more severely narrowed coronary arteries, larger areas of complicated lesions, and lower adenosine-stimulated myocardial blood flow. [12] [13] [14] A more comprehensive evaluation of ESR1 is required to determine the mechanism(s) underlying these observed associations.
Our results add substantially to recent evidence that a mechanism based on ESR1 variation contributes to a range of important estrogen-dependent characteristics, including responses of the lipid profile to hormone replacement therapy and risk of fracture. 15, 16 For nonfatal MI events in the populations included in this study, the population risk attributable to the ESR1 c.454-397CC genotype was 6.4%, which would correspond among US men 17 to approximately 25 000 of such events each year and incur substantial hospital and medical expenses.
